These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26924092)

  • 21. Efficacy and safety of human placental extract for alcoholic and nonalcoholic steatohepatitis: an open-label, randomized, comparative study.
    Choi JY; Lee K; Lee SM; Yoo SH; Hwang SG; Choi JY; Lee SW; Hwang JS; Kim KK; Kang HC; Cheon GJ; Park YM
    Biol Pharm Bull; 2014; 37(12):1853-9. PubMed ID: 25590055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
    Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V;
    Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264
    [No Abstract]   [Full Text] [Related]  

  • 24. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
    Piazza NA; Singal AK
    Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Mathurin P; Nagy LA
    Gastroenterology; 2016 Jun; 150(8):1695-7. PubMed ID: 27155520
    [No Abstract]   [Full Text] [Related]  

  • 26. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical and biochemical characteristics in patients with histology compatible with steatothepatitis in National Hospital Arzobispo Loayza, Lima, Peru, from 2010 to 2012].
    Alegría Matos PH; Tafur Cabello KS; Lozano Miranda A; Loza Munarriz C; Lozano Miranda Z
    Rev Gastroenterol Peru; 2015; 35(3):236-42. PubMed ID: 26397280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing liver fibrosis in patients with NAFLD and the road ahead.
    Nobili V; Miele L; Alisi A
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
    [No Abstract]   [Full Text] [Related]  

  • 31. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders.
    Jamshed F; Dashti F; Ouyang X; Mehal WZ; Banini BA
    World J Gastroenterol; 2023 Mar; 29(12):1824-1837. PubMed ID: 37032732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives.
    Gitto S; Bihl F; Schepis F; Caputo F; Berenguer M
    Biomed Res Int; 2019; 2019():8691502. PubMed ID: 31380439
    [No Abstract]   [Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.
    Cole BK; Feaver RE; Wamhoff BR; Dash A
    Expert Opin Drug Discov; 2018 Feb; 13(2):193-205. PubMed ID: 29190166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges and opportunities in bringing new medications to market for pediatric patients.
    Upadhyaya HP; Gault L; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
    [No Abstract]   [Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease.
    Thrasher T; Abdelmalek MF
    N C Med J; 2016; 77(3):216-9. PubMed ID: 27154894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
    Siddiqui MS; Harrison SA; Abdelmalek MF; Anstee QM; Bedossa P; Castera L; Dimick-Santos L; Friedman SL; Greene K; Kleiner DE; Megnien S; Neuschwander-Tetri BA; Ratziu V; Schabel E; Miller V; Sanyal AJ;
    Hepatology; 2018 May; 67(5):2001-2012. PubMed ID: 29059456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future trends in the treatment of non-alcoholic steatohepatitis.
    Fiorucci S; Biagioli M; Distrutti E
    Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alcoholic steatohepatitis: what's new in 2012?].
    Goossens N; Ditisheim S; Lanthier N; Spahr L; Hadengue A
    Rev Med Suisse; 2012 Sep; 8(352):1646-8, 1650-1. PubMed ID: 22988723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
    Meyer EL; Mesenbrink P; Di Prospero NA; Pericàs JM; Glimm E; Ratziu V; Sena E; König F;
    PLoS One; 2023; 18(3):e0281674. PubMed ID: 36893087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leveraging Clinical Pharmacology to Optimize Drug Development for Nonalcoholic Steatohepatitis and Cholestatic Liver Diseases: Workshop Report.
    Kim I; Seo S
    Clin Pharmacol Ther; 2021 Feb; 109(2):292-294. PubMed ID: 32740920
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.